vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.
Local Bounti Corporation is the larger business by last-quarter revenue ($12.5M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -69.8%, a 93.3% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 23.7%). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
ABUS vs LOCL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $12.5M |
| Net Profit | $2.5M | $-8.7M |
| Gross Margin | — | 12.2% |
| Operating Margin | 13.9% | -106.1% |
| Net Margin | 23.5% | -69.8% |
| Revenue YoY | 522.2% | 23.7% |
| Net Profit YoY | 112.7% | 76.0% |
| EPS (diluted) | $0.01 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $12.2M | ||
| Q2 25 | $10.7M | $12.1M | ||
| Q1 25 | — | $11.6M | ||
| Q4 24 | — | $10.1M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | — | $9.4M | ||
| Q1 24 | — | $8.4M |
| Q4 25 | — | $-8.7M | ||
| Q3 25 | — | $-26.4M | ||
| Q2 25 | $2.5M | $-21.6M | ||
| Q1 25 | — | $-37.7M | ||
| Q4 24 | — | $-36.3M | ||
| Q3 24 | — | $-34.3M | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 12.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 9.4% |
| Q4 25 | — | -106.1% | ||
| Q3 25 | — | -149.4% | ||
| Q2 25 | 13.9% | -127.7% | ||
| Q1 25 | — | -135.6% | ||
| Q4 24 | — | -166.6% | ||
| Q3 24 | — | -176.0% | ||
| Q2 24 | — | -146.8% | ||
| Q1 24 | — | -122.9% |
| Q4 25 | — | -69.8% | ||
| Q3 25 | — | -216.6% | ||
| Q2 25 | 23.5% | -178.3% | ||
| Q1 25 | — | -324.6% | ||
| Q4 24 | — | -360.1% | ||
| Q3 24 | — | -335.2% | ||
| Q2 24 | — | -267.6% | ||
| Q1 24 | — | -286.9% |
| Q4 25 | — | $1.52 | ||
| Q3 25 | — | $-1.18 | ||
| Q2 25 | $0.01 | $-1.63 | ||
| Q1 25 | — | $-4.32 | ||
| Q4 24 | — | $-4.24 | ||
| Q3 24 | — | $-4.01 | ||
| Q2 24 | — | $-3.00 | ||
| Q1 24 | — | $-2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $4.2M |
| Total DebtLower is stronger | $0 | $483.1M |
| Stockholders' EquityBook value | $83.0M | $-166.2M |
| Total Assets | $103.3M | $410.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | $37.4M | $5.3M | ||
| Q1 25 | — | $18.0M | ||
| Q4 24 | — | $937.0K | ||
| Q3 24 | — | $317.0K | ||
| Q2 24 | — | $9.7M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | — | $483.1M | ||
| Q3 25 | — | $484.9M | ||
| Q2 25 | $0 | $478.3M | ||
| Q1 25 | — | $480.0M | ||
| Q4 24 | — | $436.8M | ||
| Q3 24 | — | $398.4M | ||
| Q2 24 | — | $374.0M | ||
| Q1 24 | — | $329.8M |
| Q4 25 | — | $-166.2M | ||
| Q3 25 | — | $-158.1M | ||
| Q2 25 | $83.0M | $-132.7M | ||
| Q1 25 | — | $-134.5M | ||
| Q4 24 | — | $-100.5M | ||
| Q3 24 | — | $-65.6M | ||
| Q2 24 | — | $-32.8M | ||
| Q1 24 | — | $-9.4M |
| Q4 25 | — | $410.5M | ||
| Q3 25 | — | $417.8M | ||
| Q2 25 | $103.3M | $426.8M | ||
| Q1 25 | — | $447.2M | ||
| Q4 24 | — | $428.0M | ||
| Q3 24 | — | $430.8M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $413.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-3.1M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -29.1% |
| Capex IntensityCapex / Revenue | 0.0% | 3.9% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.1M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | $-15.7M | $-8.7M | ||
| Q1 25 | — | $-9.6M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $-17.2M | ||
| Q2 24 | — | $-4.0M | ||
| Q1 24 | — | $-7.1M |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-10.1M | ||
| Q2 25 | — | $-14.6M | ||
| Q1 25 | — | $-14.5M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-30.0M | ||
| Q2 24 | — | $-28.8M | ||
| Q1 24 | — | $-42.1M |
| Q4 25 | — | -29.1% | ||
| Q3 25 | — | -82.8% | ||
| Q2 25 | — | -121.0% | ||
| Q1 25 | — | -125.1% | ||
| Q4 24 | — | -85.3% | ||
| Q3 24 | — | -293.1% | ||
| Q2 24 | — | -305.4% | ||
| Q1 24 | — | -501.8% |
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | 0.0% | 48.9% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 97.6% | ||
| Q3 24 | — | 125.0% | ||
| Q2 24 | — | 263.0% | ||
| Q1 24 | — | 417.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
